• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长期随访的肝细胞癌患者中的克隆进化。

Clonal evolution in long-term follow-up patients with hepatocellular carcinoma.

机构信息

The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.

The Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China.

出版信息

Int J Cancer. 2018 Dec 1;143(11):2862-2870. doi: 10.1002/ijc.31844. Epub 2018 Oct 3.

DOI:10.1002/ijc.31844
PMID:30183077
Abstract

To investigate tumor clonal evolution in hepatocellular carcinoma (HCC), we collected 31 tumor samples,16 peritumor samples and matched PBMCs from 11 long-term follow-up patients with HCC. Whole-exome sequencing was performed to obtain SNVs and CNVs for each sample. An average of 652.2 somatic mutations were identified in each patient and the mean percentage of nonubiquitous tumor mutations was 63.7% (range, 0.7%-100%), reflecting the variety of tumor heterogeneity. Further analysis of clonal evolution was conducted based on mutation clustering results and revealed that different clonal evolution patterns indeed existed in single and multifocal HCC while these patterns were significantly correlated to patients' clinical course. These patterns clearly demonstrated different mechanisms of tumor recurrence. During tumor clonal evolution, potential therapeutic targets also emerged and vanished dynamically. Moreover, mutation analysis revealed that the contribution of mutational signature was correlated with clonal evolution history. Target sequencing of follow-up plasma samples also confirmed that ctDNA level could dynamically reflect tumor clonal/subclonal burden. By investigating clonal evolution in HCC patients, our analysis revealed that different patterns indeed existed during HCC progression and proposed a novel strategy for identifying the origin of recurrent tumor as well as optimizing treatment selection.

摘要

为了研究肝癌(HCC)中的肿瘤克隆进化,我们收集了 11 例长期随访 HCC 患者的 31 个肿瘤样本、16 个肿瘤旁样本和配对的 PBMCs。对每个样本进行全外显子组测序以获得 SNVs 和 CNVs。每位患者平均鉴定出 652.2 个体细胞突变,非同义肿瘤突变的平均百分比为 63.7%(范围:0.7%-100%),反映了肿瘤异质性的多样性。基于突变聚类结果进一步分析克隆进化,结果表明在单发和多灶性 HCC 中确实存在不同的克隆进化模式,这些模式与患者的临床病程显著相关。这些模式清楚地显示了肿瘤复发的不同机制。在肿瘤克隆进化过程中,潜在的治疗靶点也动态地出现和消失。此外,突变分析表明突变特征的贡献与克隆进化史相关。对随访血浆样本的靶向测序也证实 ctDNA 水平可以动态反映肿瘤克隆/亚克隆负担。通过研究 HCC 患者的克隆进化,我们的分析表明 HCC 进展过程中确实存在不同的模式,并提出了一种新的策略来识别复发性肿瘤的起源以及优化治疗选择。

相似文献

1
Clonal evolution in long-term follow-up patients with hepatocellular carcinoma.长期随访的肝细胞癌患者中的克隆进化。
Int J Cancer. 2018 Dec 1;143(11):2862-2870. doi: 10.1002/ijc.31844. Epub 2018 Oct 3.
2
Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma.循环肿瘤DNA分析揭示晚期肝细胞癌的克隆进化和实时疾病进展。
Int J Cancer. 2017 Sep 1;141(5):977-985. doi: 10.1002/ijc.30798. Epub 2017 Jun 7.
3
Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA.全外显子组测序从肿瘤和循环肿瘤 DNA 的角度揭示肝癌的转移潜能。
Hepatol Int. 2023 Dec;17(6):1461-1476. doi: 10.1007/s12072-023-10540-x. Epub 2023 May 23.
4
Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.肝细胞癌长期随访患者循环肿瘤 DNA 和蛋白质生物标志物的综合液体分析。
Clin Cancer Res. 2019 Sep 1;25(17):5284-5294. doi: 10.1158/1078-0432.CCR-18-3477. Epub 2019 Jun 19.
5
Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma.多灶性肝细胞癌的基因组和转录组异质性。
Ann Oncol. 2019 Jun 1;30(6):990-997. doi: 10.1093/annonc/mdz103.
6
Molecular evolution in different subtypes of multifocal hepatocellular carcinoma.多灶性肝细胞癌不同亚型的分子进化。
Hepatol Int. 2023 Dec;17(6):1429-1443. doi: 10.1007/s12072-023-10551-8. Epub 2023 Jun 5.
7
Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.原发性和复发性肝细胞癌的基因组和表观基因组特征。
Gastroenterology. 2019 Dec;157(6):1630-1645.e6. doi: 10.1053/j.gastro.2019.09.005. Epub 2019 Sep 24.
8
Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.克服肿瘤内异质性,鉴定肝癌潜在治疗靶点。
J Hepatol. 2017 Aug;67(2):293-301. doi: 10.1016/j.jhep.2017.03.005. Epub 2017 Mar 18.
9
Single-Cell DNA Sequencing Reveals Punctuated and Gradual Clonal Evolution in Hepatocellular Carcinoma.单细胞 DNA 测序揭示肝细胞癌中的突发和渐进的克隆进化。
Gastroenterology. 2022 Jan;162(1):238-252. doi: 10.1053/j.gastro.2021.08.052. Epub 2021 Sep 2.
10
Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity.从空间和时间基因组异质性推断多灶性肝癌的进展
Oncotarget. 2016 Jan 19;7(3):2867-77. doi: 10.18632/oncotarget.6558.

引用本文的文献

1
Prognostic significance of circulating tumor DNA detection and quantification in cervical cancer: a systematic review and meta-analysis.循环肿瘤DNA检测与定量在宫颈癌中的预后意义:一项系统评价和荟萃分析
Front Oncol. 2025 Apr 4;15:1566750. doi: 10.3389/fonc.2025.1566750. eCollection 2025.
2
Clinical Application of Different Liquid Biopsy Components in Hepatocellular Carcinoma.不同液体活检成分在肝细胞癌中的临床应用
J Pers Med. 2024 Apr 15;14(4):420. doi: 10.3390/jpm14040420.
3
Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma.
用于预测肝细胞癌预后和治疗结果的肿瘤突变负荷
Int J Mol Sci. 2023 Feb 8;24(4):3441. doi: 10.3390/ijms24043441.
4
Pien Tze Huang Inhibits Migration and Invasion of Hepatocellular Carcinoma Cells by Repressing PDGFRB/YAP/CCN2 Axis Activity.片仔癀通过抑制血小板衍生生长因子受体β/Yes相关蛋白/结缔组织生长因子轴的活性来抑制肝癌细胞的迁移和侵袭。
Chin J Integr Med. 2024 Feb;30(2):115-124. doi: 10.1007/s11655-022-3533-8. Epub 2022 Aug 10.
5
Differences in actionable genomic alterations between brain metastases and non‑brain metastases in patients with non‑small cell lung cancer.非小细胞肺癌患者脑转移与非脑转移病灶之间可操作的基因组改变的差异。
Int J Oncol. 2022 Sep;61(3). doi: 10.3892/ijo.2022.5390. Epub 2022 Jul 7.
6
Biomarkers for hepatocellular carcinoma based on body fluids and feces.基于体液和粪便的肝细胞癌生物标志物。
World J Gastrointest Oncol. 2021 May 15;13(5):351-365. doi: 10.4251/wjgo.v13.i5.351.
7
Targeted therapy for hepatocellular carcinoma.肝细胞癌的靶向治疗。
Signal Transduct Target Ther. 2020 Aug 11;5(1):146. doi: 10.1038/s41392-020-00264-x.
8
Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.液体活检分析在肝细胞癌检测、预后判断和疾病监测中的应用:系统评价。
Clin Gastroenterol Hepatol. 2020 Dec;18(13):2879-2902.e9. doi: 10.1016/j.cgh.2020.04.019. Epub 2020 Apr 11.
9
Genomic and Transcriptomic Landscape of Tumor Clonal Evolution in Cholangiocarcinoma.胆管癌肿瘤克隆进化的基因组和转录组图谱
Front Genet. 2020 Mar 13;11:195. doi: 10.3389/fgene.2020.00195. eCollection 2020.
10
Does microvascular invasion in Barcelona Clinic Liver Cancer stage A multinodular hepatocellular carcinoma indicate early-stage behavior?巴塞罗那临床肝癌分期A期多结节肝细胞癌中的微血管侵犯是否提示早期行为?
Ann Transl Med. 2019 Sep;7(18):428. doi: 10.21037/atm.2019.08.114.